LY4584180 with rituximab for adults with previously treated B‑cell lymphomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, open-label study of the investigational agent LY4584180 given with rituximab in adults who have received prior systemic therapy for B‑cell non‑Hodgkin lymphomas. The trial focuses on safety, how the drug is processed in the body (pharmacokinetics), and early signs of anti‑tumor activity, with each participant followed for about nine months or longer including screening. Eligible participants must have measurable disease, have recovered from prior therapy, and typically have had at least two prior lines of systemic treatment or be ineligible for available therapy. Key exclusions include active second cancers, active CNS involvement by lymphoma, or known cytomegalovirus infection, and enrollment occurs at selected U.S. cancer centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:

  * Diffuse large B-cell lymphoma - not otherwise specified
  * High-grade B-cell lymphoma
  * Diffuse large B-cell lymphoma - transformed from indolent lymphomas
  * Follicular large B-cell lymphoma
  * Follicular lymphoma
  * Other non-Hodgkin lymphoma
* Has measurable disease
* Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy

Exclusion Criteria:

* Has an active second cancer
* Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.
* Has known Cytomegalovirus infection. Participants with negative status are eligible
* Has known hepatitis B or C infection or uncontrolled HIV
* Has known significant heart disease

Where it's running

• Mayo Clinic - Scottsdale
  Scottsdale, Arizona, United States Recruiting
• City of Hope
  Duarte, California, United States Recruiting
• University of California, Los Angeles (UCLA) - Medical Center
  Los Angeles, California, United States Recruiting
• University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
  San Francisco, California, United States Recruiting
• Colorado Blood Cancer Institute
  Denver, Colorado, United States Recruiting
• University of Miami - Sylvester Cancer Center
  Miami, Florida, United States Recruiting

Study contacts

• Study coordinator: Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 1-317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• MK-1045 and Rituximab in Follicular Lymphoma

  This study tests whether adding MK-1045 to rituximab can help people with follicular lymphoma after standard therapy.

  Recruiting at 38 sites Phase 2/3 Merck Sharp & Dohme LLC · Duarte, California and 37 other locations · NCT07634471

• Mosunetuzumab and Zeprumetostat in Follicular Lymphoma

  This study tests whether a combination of Mosunetuzumab and Zeprumetostat can help adults with follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07555470

• Zanubrutinib plus obinutuzumab and lenalidomide for first-line follicular lymphoma

  This trial tests whether the combination of zanubrutinib, obinutuzumab, and lenalidomide is safe and effective as a chemotherapy-free first treatment for adults with untreated follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07299149

• Off-the-shelf CAR-T Allo-QuadCAR01-T targeting CD19 and CD20 for relapsed or refractory B‑cell cancers

  This study will test an off-the-shelf donor CAR-T that targets CD19 and CD20 to try to treat adults with relapsed or refractory B‑cell lymphomas or leukemias.

  Recruiting at 6 sites Phase 1/2 AvenCell Therapeutics, Inc. · Chicago, Illinois and 12 other locations · NCT07284433

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.